This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

US appeals court says class certification in Opana ER case requires more consideration

( July 13, 2021, 22:31 GMT | Official Statement) -- MLex Summary: Endo Pharmaceuticals has gotten antitrust claims over the drug Opana ER remanded by a US court of appeals for reconsideration of a class certification order. “As petitioners correctly point out, the district court overlooked some of their arguments regarding uninjured class members,” determined the US Court of Appeals for the Seventh Circuit. Plaintiffs are accusing Endo of conspiring to delay the introduction of a generic alternative to the pain medication.See document below. ...

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Documents

Related Sections